Table 2. Univariate analysis of predictors of tumour progression.
| Variable | Cut-off level/categories | HR | 95% CI | P value |
|---|---|---|---|---|
| Tumour focality | uni vs. multifocal | 2.25 | 0.92-5.52 | 0.0768 |
| Tumour size | ≤3 cm vs. >3 cm | 1.69 | 0.66-4.33 | 0.2718 |
| BCG treatment | no vs yes | 1.29 | 0.56-2.98 | 0.5546 |
| Stage1 | Ta vs. T1 | 1.06 | 0.72-1.56 | 0.7738 |
| Grade1 | LG vs. HG | 1.85 | 0.75-4.54 | 0.1792 |
| Concomitant CIS | without CIS vs. CIS | 1 | 0.34-2.95 | 0.9974 |
| miR-140-5p | −4.4 | 2.89 | 1.13-7.39 | 0.0267* |
| miR-142-3p | 1.01 | 3.09 | 1.26-7.6 | 0.0139* |
| miR-18a-3p | −7.02 | 4.40 | 1.72-11.29 | 0.0020* |
| miR-92a-3p | −0.555 | 5.35 | 1.81-15.53 | 0.0025* |
| miR-125b-5p | −1.74 | 0.60 | 0.23-1.53 | 0.2813 |
| miR-204-5p | −5.15 | 0.93 | 0.39-2.21 | 0.8612 |
Results of dichotomous clinical variables are expressed considering category placed in second term as the reference category
1The grade and stage of the tumours were determined according to WHO criteria [38] and TNM classification [39], respectively.
*Statistically significant
Abbreviations: CIS, Carcinoma in situ; LG, Low grade; HG, High grade; BCG, Bacillus Calmette-Guerin; HR, hazard ratio; 95%CI, confidence interval.